Suzhou Homesun Pharmaceutical Co. Ltd.

Primary objective: To investigate the pharmacokinetics of a single oral dose of the test formulation measartan potassium tablets (80 mg, manufactured by Suzhou Hongsen Pharmaceutical Co., Ltd., certified by Suzhou Hongsen Pharmaceutical Co., Ltd.) and the reference formulation measartan potassium tablets (Edarbi®, 80 mg, manufactured by Takeda Ireland Ltd., certified by Takeda Pharma A/S) in healthy adult subjects under fasting and postprandial conditions, and to evaluate the bioequivalence of the two formulations under fasting and postprandial conditions. Secondary objective: To investigate the safety of a single oral dose of the test formulation measartan potassium tablets and the reference formulation measartan potassium tablets (Edarbi®) in healthy adult subjects under fasting and postprandial conditions.

The main purpose of the study is to study the pharmacokinetics of the test preparation Eperisone Hydrochloride Tablets (Specification: 50 mg, produced by Suzhou Hongsen Pharmaceutical Co., Ltd.) and the reference preparation Eperisone Hydrochloride Tablets (Miao Na®, Specification: 50 mg; produced by Eisai (China) Pharmaceutical Co., Ltd.) in healthy adult subjects after a single oral administration in the fasting or fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. The secondary purpose of the study is to evaluate the safety of the test preparation Eperisone Hydrochloride Tablets and the reference preparation Eperisone Hydrochloride Tablets (Miao Na®) in healthy adult subjects.

Primary objective: To study the pharmacokinetics of the test preparation bisoprolol amlodipine tablets (specifications: 5 mg bisoprolol fumarate and 5 mg amlodipine besylate (calculated as amlodipine), produced by Suzhou Hongsen Pharmaceutical Co., Ltd.) and the reference preparation bisoprolol amlodipine tablets (specifications: 5 mg bisoprolol fumarate and 5 mg amlodipine besylate (calculated as amlodipine), produced by Egis Pharmaceuticals PLC) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test preparation (T) bisoprolol amlodipine tablets and the reference preparation (R) bisoprolol amlodipine tablets (Kangxinan®) in healthy subjects after a single oral administration in the fasting and fed state.